Cargando…

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer

In locally advanced rectal cancer, radiotherapy (RT) followed by surgery have improved locoregional control, but distant recurrences remain frequent. Although checkpoint inhibitors have demonstrated objective response in several cancers, the clinical benefit of PD-1/PD-L1 blockade remains uncertain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boustani, Jihane, Derangère, Valentin, Bertaut, Aurélie, Adotevi, Olivier, Morgand, Véronique, Charon-Barra, Céline, Ghiringhelli, François, Mirjolet, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563314/ https://www.ncbi.nlm.nih.gov/pubmed/32927784 http://dx.doi.org/10.3390/cells9092071

Ejemplares similares

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

About the Influence of PEG Spacers on the Cytotoxicity of Titanate Nanotubes-Docetaxel Nanohybrids against a Prostate Cancer Cell Line
por: Loiseau, Alexis, et al.
Publicado: (2021)

The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
por: Boustani, Jihane, et al.
Publicado: (2019)

Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021)

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
por: Boustani, Jihane, et al.
Publicado: (2021)

Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
por: Bergeron, Anthony, et al.
Publicado: (2023)

Induction of pyroptosis in colon cancer cells by LXRβ
por: Rébé, Cédric, et al.
Publicado: (2015)

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
por: Galland, Loïck, et al.
Publicado: (2021)

In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
por: Laurent, P.A., et al.
Publicado: (2020)

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
por: Isambert, Nicolas, et al.
Publicado: (2018)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Online adaptive radiotherapy and dose delivery accuracy: A retrospective analysis
por: Bessieres, Igor, et al.
Publicado: (2023)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use
por: Chevrier, Sandy, et al.
Publicado: (2022)

The radio-induced immune response: ballistics is key
por: Mirjolet, Céline, et al.
Publicado: (2023)

HSP70 is a negative regulator of NLRP3 inflammasome activation
por: Martine, Pierre, et al.
Publicado: (2019)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021)

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction
por: Chevriaux, Angélique, et al.
Publicado: (2020)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
por: Ghiringhelli, François, et al.
Publicado: (2023)

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization
por: Courtaut, Flavie, et al.
Publicado: (2015)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer
por: Mirjolet, Céline, et al.
Publicado: (2016)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
por: Perrichet, Anaïs, et al.
Publicado: (2020)

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images
por: Le Page, Anne Laure, et al.
Publicado: (2021)

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2018)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors
por: Loiseau, Alexis, et al.
Publicado: (2019)

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
por: Cordonnier, Marine, et al.
Publicado: (2020)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
por: Hervé, Laure, et al.
Publicado: (2022)

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
por: Roussot, Nicolas, et al.
Publicado: (2023)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hb5ekh5intdd2gdegepcabropk